Webdisclosure.com

SANOFI-AVENTIS (EPA:SAN)

28/09/2021 08:00

Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

19/09/2021 17:30

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

14/09/2021 15:26

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

08/09/2021 14:08

Sanofi to acquire Kadmon to further strengthen growth of transplant business

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

30/08/2021 07:00

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

25/08/2021 18:31

Sanofi: Information concerning the total number of voting rights and shares - July 2021

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

05/08/2021 12:00

Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

22/07/2021 18:02

Sanofi: Information concerning the total number of voting rights and shares - June 2021

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

29/06/2021 10:00

Sanofi launches dedicated vaccines mRNA Center of Excellence

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

28/06/2021 08:00

Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial

Voir tous les communiqués de SANOFI-AVENTIS

«
3
4
5
6
7
8
9
10